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In November 2011, the Third European Consensus Conference on Diagnosis and Treatment of Germ-Cell Cancer
(GCC) was held in Berlin, Germany. This third conference followed similar meetings in 2003 (Essen, Germany) and
2006 (Amsterdam, The Netherlands) [Schmoll H-J, Souchon R, Krege S et al. European consensus on diagnosis and
treatment of germ-cell cancer: a report of the European Germ-Cell Cancer Consensus Group (EGCCCG). Ann Oncol
2004; 15: 1377–1399; Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and
treatment of germ-cell cancer: a report of the second meeting of the European Germ-Cell Cancer Consensus group
(EGCCCG): part I. Eur Urol 2008; 53: 478–496; Krege S, Beyer J, Souchon R et al. European consensus conference
on diagnosis and treatment of germ-cell cancer: a report of the second meeting of the European Germ-Cell Cancer
Consensus group (EGCCCG): part II. Eur Urol 2008; 53: 497–513]. A panel of 56 of 60 invited GCC experts from all
across Europe discussed all aspects on diagnosis and treatment of GCC, with a particular focus on acute and late
toxic effects as well as on survivorship issues.
The panel consisted of oncologists, urologic surgeons, radiooncologists, pathologists and basic scientists, who are all
actively involved in care of GCC patients. Panelists were chosen based on the publication activity in recent years.
Before the meeting, panelists were asked to review the literature published since 2006 in 20 major areas concerning all
aspects of diagnosis, treatment and follow-up of GCC patients, and to prepare an updated version of the previous
recommendations to be discussed at the conference. In addition, ∼50 E-vote questions were drafted and presented at
the conference to address the most controversial areas for a poll of expert opinions. Here, we present the main
recommendations and controversies of this meeting. The votes of the panelists are added as online supplements.
Key words: consensus conference, diagnosis, germ-cell cancer, late toxic effects, long-term follow-up, treatment
diagnosis, management of the primary
tumor and staging
Germ-cell cancer (GCC), cytogenetically characterized by
abnormalities of 12p, is the most frequent malignancy in male
Caucasians aged 15–40 years. The majority of patients present
with a primary tumor in the testis. However, as GCC may also
occur in midline structures of the body, an extragonadal germ-
cell cancer (EGCC) should always be considered in young men
with a retroperitoneal, supraclavicular or mediastinal mass.
Important insights have recently been obtained regarding
the etiology of GCC. These relate to the recognition of
established risk factors, supposed to be interlinked to each
other according to the so-called testicular dysgenesis syndrome
and disorders of sex development [1]. In addition, high-risk
alleles have been identified [2, 3]. The most significant
conclusion is that all these parameters are in accordance with
an embryonic initiation of the pathogenesis of GCC, i.e. related
to the initial formation and secondary development of the
testes.
A histopathological examination of the orchiectomy
specimen will establish the diagnosis in patients with gonadal
GCC. The histopathological report must address the following
issues: localization and size of the tumor, multiplicity, tumor
extension (rete testis, tunica albuginea, tunica vaginalis,
spermatic cord, scrotum), pT category according to the most
recent International Union Against Cancer (UICC)
classification, histological type (WHO-ICD-O-M), the presence
or absence of carcinoma-in situ/testicular intraepithelial
neoplasia (CIS/TIN) (synonymous: intratubular germ-cell
neoplasia) and the presence or absence of vascular invasion of
blood or lymphatic vessels. In tumors with mixed structures,
each individual component and its estimated relative
proportion must be documented. Similarly, evidence of
syncytiotrophoblasts should be indicated in seminoma as well
as any sarcomatous elements in spermatocytic seminoma as
recommended by the World Health Organization [4–6].
Immunohistochemistry must include detection of alpha-
fetoprotein (AFP) and human chorionic gonadotropin (HCG)
for identification of yolk sac tumor and choriocarcinoma,
respectively [7]. Vascular invasion can be detected
morphologically, supported by immunohistochemical detection
of CD31/FVIII. Recent studies demonstrate that applications of
pluripotency-related markers (OCT4, NANOG, AP-2γ or
LIN28) are highly informative for the detection of CIS/TIN,
seminoma and EC, to be combined with different fixation
protocols [8]. Because of the clinical importance, it is highly
recommended that all histological specimens be assessed by a
pathologist experienced in GCC pathology [9, 10].
The issue of a contralateral biopsy in patients with a
unilateral gonadal GCC divided opinions [11]. While the need
for informing all patients about the pros and cons of a
contralateral biopsy remained undisputed, only about a third of
panelists recommended a contralateral biopsy at least to high-
risk patients (supplementary material S1, available at Annals of
Oncology online) followed by radiotherapy with 16–20 Gy to
eliminate CIS/TIN (supplementary material S2, available at
Annals of Oncology online). As the benefit of CIS/TIN
detection and the possibility of assessing spermatogenesis,
fertility is counterbalanced by infertility in 100% and in
hypogonadism in ∼30% of patients after radiotherapy with the
subsequent need for testosterone supplementation, the
majority of panelists opted against routine biopsies to detect
CIS/TIN. Yet, as the majority of patients with untreated CIS/
TIN in the contralateral testis will eventually develop overt
GCC within the next 10 years, surveillance programs, e.g. by
regular clinical examination and testicular ultrasound, are
mandatory and the patients need to be informed that a
contralateral GCC might develop with subsequent
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hypogonadism and need for testosterone replacement after
treatment.
In EGCC, the necessity of testicular biopsies in patients with
proven EGCC was likewise questioned. The majority of
panelists voted against performing biopsies in EGCC patients
when both of the testes were normal upon clinical examination
and ultrasound (supplementary material S3, available at Annals
of Oncology online). Spiral computerized tomography (CT)
scans of the thorax, abdomen and pelvis remain the staging
investigation of choice (Table 1) [12]. Diagnostic imaging of
the brain is recommended in patients with visceral metastases
and mandatory in the presence neurological symptoms
(supplementary material S4, available at Annals of Oncology
online). Magnetic resonance tomography imaging (MRI) as an
alternative staging procedure to CT scanning should be
reserved to selected patient populations (e.g. intolerance to
intravenous contrast agents) and to institutions with special
expertize using MRI (supplementary material S5, available at
Annals of Oncology online). Positron electron tomography–
computerized tomography scanning (PET–CT) has no role as
a staging procedure due to its low additional diagnostic yield
over CT or MRI scans and its additional radiation exposure
[13, 14].
Serum tumor markers AFP, HCG and lactate dehydrogenase
(LDH) should be determined in all patients before and after
orchiectomy and in patients with metastatic disease also
immediately before chemotherapy. In metastatic patients, these
pre-chemotherapy markers—and not the pre-orchiectomy
markers—should be used for the correct allocation to the
IGCCG prognostic category (supplementary material S6,
available at Annals of Oncology online) [4–6, 15, 16]. Particular
attention should be paid to patients with radiological stage I
disease and elevated tumor markers: patients should be
monitored with frequent post-orchiectomy serum marker
determinations until complete marker normalization before
these patients are classified as having true stage I disease. All
other patients with an increase of serum tumor markers after
orchiectomy must be considered as having metastatic disease.
Patients with normal serum tumor markers and equivocal
retroperitoneal metastases in CT or MRI scans should be
followed closely by repeat scanning or in case of a non-
seminoma may receive upfront staging retroperitoneal
lymph-node dissection (RPLND) or before a definitive
treatment decision is made.
clinical stage I disease in seminoma
and non-seminoma
Clinical stage I in seminoma and non-seminoma is defined as
disease limited to the testes with no radiological evidence of
metastatic disease and normal serum tumor markers after
orchiectomy.
In respect to the optimal management of seminoma stage I,
the discussion revealed a spectrum of opinions among
panelists (Table 2). The first discussion circled around the issue
of prognostic factors. In contrast to the initial analyses from
the Canadian group, rete testis infiltration and tumor size >4
cm could not be validated in two prospective series for the
identification of seminoma patients with a high risk of occult
metastases [17, 18]. However, contrary to these most recent
publications, about one half of the panelists still believed that
these factors are useful in decision making in seminoma stage I
(supplementary material S7, available at Annals of Oncology
online), since at least the negative predictive value of these
factors has been prospectively shown in the most recent
Spanish trial [19]. The second discussion focused on the
optimal management strategy. Here, no consensus could be
achieved. Whereas one-third of panelists considered
Table 1. Initial management of patients with suspected GCC
History and clinical examination
Testicular ultrasound
Serum tumor markers AFP, HCG and LDHa
CT of the thorax, abdomen and pelvisb
Orchiectomy in patients with gonadal diseasec
Detailed histopathological report
Option of semen cryopreservation in patients scheduled for chemotherapy
aAlso after orchiectomy in all patients with elevated markers as well as
immediately before chemotherapy in patients with metastatic disease.
bCT or MRI scan also of the brain in patients with visceral metastases
and/or neurological symptoms or signs.
cOrchiectomy should be delayed until completion of chemotherapy in
patients with advanced disease at initial presentation and/or imminent
organ failure. Patients with normal testes and suspected extragonadal
germ-cell cancer (EGCC) may or may not have a testicular biopsy.
GCC, germ-cell cancer; AFP, alpha-fetoprotein; HCG, human chorionic
gonadotropin; LDH, lactate dehydrogenase; CT, computerized
tomography; MRI, magnetic resonance imaging.
Table 2. Strategies in clinical stage I seminoma and non-seminoma
Seminoma
Risk factors for occult
metastases:a
Tumor size ≥4 cm
Invasion of rete testis
Treatment options: Surveillance (preferred in low risk
patients)
One cycle carboplatin AUC 7
Adjuvant paraaortic radiation 20 Gyb
Non-seminoma
Risk factors for occult
metastases:
Vascular or lymphatic invasion
Treatment options: Surveillance (preferred in low risk
patients)
One adjuvant cycle BEP
Two adjuvant cycles BEP
Primary RPLND (rarely indicated)c
aValidity of risk factors have been challenged in recent analyses.
bRadiotherapy was a less favored adjuvant treatment option due to the
long-term risk of induction of secondary malignancies.
cIndicated, e.g. in stage I patients with retroperitoneal lymph-nodes of
equivocal size who are unwilling to accept surveillance (see the text for
further details).
AUC, area under the curve; Gy, Gray; BEP, bleomycin, etoposide, cisplatin;
RPLND, retroperitoneal lymph-node dissection.
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surveillance the preferred treatment strategy in all stage I
seminoma regardless of the risk factors for relapse, others
opted for surveillance in ‘low-risk’ patients with a relapse rate
of 5%–12%, and adjuvant treatment in ‘high-risk’ patients as
had been pursued in the Spanish cooperative trial [19]. The
use of radiotherapy as adjuvant treatment was less favored
among panelists compared with single-agent carboplatin,
because of concerns about the induction of secondary tumors
even by reduced radiation doses and fields. On the other hand,
a minority of panelists still considered surveillance, adjuvant
carboplatin and adjuvant radiation as equal options
irrespective of the risk factors (supplementary material S8,
available at Annals of Oncology online) [18–24].
In non-seminoma, vascular invasion remains the most
important prospectively validated and most widely accepted
risk factor that can be used for treatment stratification [9].
Patients without vascular invasion have a low risk of occult
metastatic disease/relapse of around 14%. In contrast, the
patients with vascular invasion in the primary tumor have a
high risk of occult metastatic disease and relapse of ∼50%. Yet,
the clinical decisions based upon these data remained
controversial (Table 2). About one-third of panelists each
favored surveillance in all non-seminoma stage I irrespective of
the risk factors, surveillance in low risk and one or two
adjuvant cycles of cisplatin, etoposide, bleomycin (BEP) in
high-risk patients, respectively. Therefore, adjuvant
chemotherapy remained the favored strategy in high-risk
clinical stage I non-seminoma. Upfront staging RPLND in all
patients was favored only by a small minority of panelists
(supplementary material S9, available at Annals of Oncology
online) [9, 25–29].
Thus, the optimal management of clinical stage I seminoma
and non-seminoma remains an area of debate. The risks and
benefits of each strategy must be discussed with patients in
respect to its immediate and long-term impact, and the patient
actively involved in the final decision. Non-compliance with
surveillance strategies remained some areas of concern, which
will have to be studied prospectively [30, 31].
first-line treatment in metastatic
seminoma and non-seminoma
In early-stage IIA seminoma with small retroperitoneal lymph-
node metastases <2 cm, radiotherapy was still considered as an
adequate treatment option, but chemotherapy was seen as an
alternative or even preferred option among panelists avoiding
an ∼10% relapse rate (supplementary material S10, available at
Annals of Oncology online) [18, 32]. In early-stage IIB
seminoma, the majority of panelists favored chemotherapy
with three cycles of BEP or four cycles of cisplatin and
etoposide (EP) over radiation treatment (supplementary
material S11, available at Annals of Oncology online) (Table 3)
[32].
Patients with metastatic seminoma and non-seminoma
should be classified according to the IGCCCG prognostic
classification [16]. According to the panelists, classic
‘Indiana BEP’ remains the standard of care in metastatic
seminoma and non-seminoma [33, 34]. Pre- and post-
hydration helps us to prevent renal toxicity. Routine
furosemide or mannitol is not required. Neutropenic fever
after BEP is infrequent and growth factor support is rarely
needed except in individual patients with very advanced
metastatic disease and in patients undergoing salvage
treatment, who have a higher risk of febrile neutropenia.
Growth factor support, empiric antibiotic treatment and
antiemetic prophylaxis should be given according to the
published guidelines. In ‘good prognosis’ patients according
to IGCCCG (Table 4), three cycles of BEP were preferred to
four cycles of EP [33, 34]. The latter were recommended to
be used in ‘good prognosis’ patients with contraindications
to bleomycin. Despite the recent European intergroup trial
that prospectively compared four cycles of BEP with or
without additional paclitaxel four cycles of BEP remain the
standard treatment in patients with ‘intermediate prognosis’
(supplementary material S12, available at Annals of Oncology
online) [35]. Four cycles of BEP also remain the standard
treatment in patients with ‘poor prognosis’ (supplementary
material S13, available at Annals of Oncology online) [36].
In intermediate and poor prognosis patients with
contraindications to bleomycin, the equally effective
combination of cisplatin, etoposide and ifosfamide (VIP)
should be used instead of BEP (Table 3). Until the
publication of an ongoing French prospective, randomized
trial, the majority of panelists did not recommend
intensification of first-line treatment by high-dose
chemotherapy (HDCT) or recommended to limit the use of
HDCT to patients with the highest risk of treatment failure
(e.g. extensive liver, bone or brain metastases)
(supplementary material S13, available at Annals of Oncology
online). Patients with an inadequate tumor marker decline
should continue to complete first-line treatment
(supplementary material S14, available at Annals of Oncology
online). Only a minority of panelists recommended
switching to intensifying chemotherapy in patients with an
inadequate marker decline [37, 38]. To avoid overtreatment,
Table 3. First-line chemotherapy regimens in metastatic seminoma and
non-seminoma
BEP (repeat cycles every 3 weeks)a reference [97]
Cisplatin 20 mg/m2 Day 1–5
Etoposide 100 mg/m2 Day 1–5
Bleomycin 30 mg Day 1, 8, 15
EP (repeat cycles every 3 weeks)b reference [33]
Cisplatin 20 mg/m2 Day 1–5
Etoposide 100 mg/m2 Day 1–5
VIP (repeat cycles every 3 weeks)c reference [98]
Cisplatin 20 mg/m2 Day 1–5
Etoposide 75 mg/m2 Day 1–5
Ifosfamide 1,2 g Day 1–5
aThree cycles BEP in IGCCCG ‘good prognosis’ patients; four cycles BEP
in IGCCCG ‘intermediate prognosis’ and ‘poor prognosis’ patients.
bFour cycles EP only in IGCCCG ‘good prognosis’ patients with
contraindications to bleomycin.
cFour cycles VIP only in IGCCCG ‘intermediate risk‘ and ‘poor risk’
patients with contraindications to bleomycin.
VIP, cisplatin, etoposide and ifosfamide.
Annals of Oncology reviews
Volume 24 | No. 4 | April 2013 doi:10.1093/annonc/mds579 | 
 at Institute of Social Studies on A
ugust 8, 2013
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
caution should be exercised in initiating chemotherapy in
stage IIA non-seminoma with normal markers and equivocal
or minimally enlarged retroperitoneal nodes. As some of
these patients may indeed have pathological stage I disease,
close surveillance or staging RPLND is recommended.
residual tumor resection after
first-line chemotherapy
Seminoma with residual tumors after chemotherapy should not
be scheduled for post-chemotherapy residual tumor resections
(PC-RTR) due to the high morbidity and small therapeutic gain
of the procedure in this group of patients. Seminoma with lesions
≥3 cm can be evaluated by PET–CT not earlier than 8 weeks
after completion of chemotherapy—the only subgroup of GCC
patients in whom PET–CT is recommended (supplementary
material S15, available at Annals of Oncology online) [39]. The
negative predictive value of PET–CT scans is high, and seminoma
with negative PET–CT scans should be followed irrespective of
the size of the residual lesion. The positive predictive value of a
PET–CT scan is less reliable. In PET–CT positive patients after
chemotherapy either biopsy, close observation with serial CT
scans or, possibly, repeat PET–CT scans were recommended by
the majority of panelists (supplementary material S16, available at
Annals of Oncology online).
According to the panelists, PC-RTR is recommended in all
non-seminoma patients with residual tumors ≥ 1 cm within
4–8 weeks after chemotherapy (supplementary material S17,
available at Annals of Oncology online) comprising the left or
right template plus all areas of initial tumor sites. Only a
minority of panelists opted for a full bilateral resection in all
patients (supplementary material S18, available at Annals of
Oncology online) [40–43]. In patients with retroperitoneal as
well as pulmonary residual lesions, no consensus as to the
optimal management could be achieved although a great
majority of panelists felt that some form of pulmonary
resections was required even in patients with necrosis in the
retroperitoneal PC-RTR specimen (supplementary material S19,
available at Annals of Oncology online) [44]. The majority of
panelist would not consider PC-RTR even in non-seminoma, if
the residual tumor is <1 cm in diameter (supplementary
material S20, available at Annals of Oncology online) [40–48].
Patients with vital cancer at the time of PC-RTR may or may
not be scheduled for two cycles of adjuvant chemotherapy
(supplementary material S21, available at Annals of Oncology
online). Patients with IGCCCG intermediate or poor
prognosis, those with >10% viable tumor residuals as well as
those with positive surgical margins have a better progression-
free, but not overall survival with adjuvant chemotherapy.
Adjuvant chemotherapy should, therefore, be discussed with
these patients, but a surveillance strategy is also justified [49].
As the success of PC-RTR highly depends on the experience
and skill of the urologic surgeon, the panelists attempted a
definition of an expert center for residual tumor surgery: 20
interventions per surgeon per year as well as immediate and
ad hoc access to an interdisciplinary team of vascular surgeons,
liver surgeons and, possibly, also orthopedic surgeons as well as
availability of high-level postoperative support (supplementary
material S22, available at Annals of Oncology online) [50, 51].
salvage treatment in seminoma and
non-seminoma
Patients with seminoma or non-seminoma who relapse after
surveillance should be treated as patients with de novo
metastatic disease with three to four cycles of BEP depending
on their IGCCCG score [16]. This extends to the patients who
relapse after adjuvant carboplatin or adjuvant radiotherapy,
although the optimal management and outcome in stage I
seminoma who relapse after adjuvant treatment are currently
unknown. Also unknown is the optimal management and
outcome in stage I non-seminoma who relapse after one or
two cycles of adjuvant BEP, who should be considered for four
cycles of conventional-dose salvage chemotherapy (Table 5).
Table 4. Prognostic classification of metastatic seminoma and non-seminoma according to IGCCCG [16]
‘Good prognosis’ (seminoma: 90% patients, 86% survival; non-seminoma: 56% patients; 92% survival)
Seminoma any primary tumor location Normal AFP, any HCG or LDH
and no extrapulmonary visceral metastases
Non-seminoma gonadal or retroperitoneal primary tumor location AFP <1000 ng/ml
and ‘low’ markers HCG <5000 U/l
and no extrapulmonary visceral metastases LDH <1.5 × ULN
‘Intermediate prognosis’ (seminoma: 10% patients, 72% survival; non-seminoma: 28% patients; 80% survival)
Seminoma any primary tumor location Normal AFP, any HCG or LDH
and extrapulmonary visceral metastases
Non-seminoma gonadal or retroperitoneal primary tumor location AFP 1000–10 000 ng/ml
and ‘intermediate’ markers’ HCG 5000–50 000 U/l
and no extrapulmonary visceral metastases LDH 1.5–10 × ULN
‘Poor prognosis’ (16% patients; >48% survival)
Non-seminoma mediastinal primary tumor AFP >10 000 ng/ml
or ‘high’ markers HCG >50 000 U/l
or extrapulmonary visceral metastases LDH >10 × ULN
AFP, alpha-fetoprotein; HCG, human chorionic gonadotropin; LDH, lactate dehydrogenase; ULN, upper limit of normal.
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Seminoma and non-seminoma patients who relapse after full
cisplatin-based first-line chemotherapy can be treated using
either conventional-dose chemotherapy (CDCT) or HDCT
[52–57]. Their prognosis should be assessed using the most
recent international prognostic score [54]. No consensus could
be reached in respect to their optimal first-salvage management
(supplementary material S23, available at Annals of Oncology
online). The opinions were divided among panelists and
ranged from using HDCT in all relapsed patients irrespective
of prognostic factors, to a risk-adapted approach using CDCT
in low-risk and HDCT in patients with a high risk of failure, as
well as to not using HDCT at all outside clinical trials, neither
in first nor in subsequent salvage treatments (Table 6). In the
discussion, a minority argued against using any HDCT in GCC
despite retrospective data in favor of HDCT in the first-salvage
setting and the fact that no conventional-dose regimen has
proven to induce long-term remissions in a relevant number of
patients when given as second or subsequent salvage treatment
[58]. HDCT should be delivered as two or three sequential
cycles using high-dose carboplatin and etoposide without
additional agents such as ifosfamide, cyclophosphamide or
thiotepa (Table 5) [52, 53, 56].
Oxaliplatin, gemcitabine and paclitaxel or combinations
thereof have shown activity in the second or third-salvage
setting and may be applied as single agents or combinations, if
these drugs had not been used previously [59, 60]. Transient
responses can also be achieved using oral etoposide.
Patients with complete remissions should be followed,
patients with residual masses after salvage chemotherapy
should be scheduled for PC-RTR within 4–6 weeks after the
normalization of tumor markers or when a low-level marker
plateau has been reached. Extensive surgery of all residual
lesions after completion of chemotherapy is an essential part of
any salvage treatment [52, 56, 59].
desperation surgery
Desperation surgery refers to the situation of a high-level
marker plateau or overtly rising markers after administration of
salvage chemotherapy in patients with potentially resectable
disease. With this approach, long-term survival may be
achieved in some patients. No conclusive data allow a definitive
prognostic assessment. HCG elevation and high AFP levels
before surgery, residual retroperitoneal disease >5 cm and a
previous RPLND have been reported to portend a poor
prognosis [61]. However, according to the panelists,
desperation surgery should be attempted in all patients in
whom no reasonable chemotherapeutic options are available,
and who have cancer that can potentially be completely
resected (supplementary material S24, available at Annals of
Oncology online).
late relapse of seminoma and
non-seminoma
Some discussions circled around the optimal definition of late
relapse. There was a clear vote that the term late relapse should
be limited to relapses occurring 2 years or later after full
cisplatin-based chemotherapy. This definition excludes patients
who relapse after adjuvant treatment or during surveillance
who are usually cured by chemotherapy alone. Patients with
late relapse represent a rare subgroup with an adverse
prognosis as well as a high frequency of teratoma and/or
non-GCC elements, who will have to be managed differently
Table 5. Salvage chemotherapy in relapsed seminoma and non-seminoma
Conventional-dose regimens [99, 100]
VIP Repeat cycles every 3 weeks 4 cycles
Cisplatin 20 mg/m2 Day 1–5
Ifosfamide 1,2 g/m2 Day 1–5
Etoposide 75 mg/m2 Day 1–5
TIP (repeat cycles every 3 weeks) 4 cycles
Cisplatin 20 mg/m2 Day 1–5
Ifosfamide 1,2 g/m2 Day 1–5
Paclitaxela 250 mg Day 1
VeIP (repeat cycles every 3 weeks) 4 cycles
Cisplatin 20 mg/m2 Day 1–5
Ifosfamide 1,2 g/m2 Day 1–5
Vinblastine 0,11 mg/kg Day 1 + 2
High-dose regimens [52, 53, 56] (require stem cell support)
Carboplatinb 500 mg/m2 Day 1–3 3 cycles
Etoposide 500 mg/m2 Day 1–3
Carboplatin 700 mg/m2 Day 1–3 2 cycles
Etoposide 750 mg/m2 Day 1–3
aPaclitaxel given as a 24 h continuous intravenous infusion.
bCarboplatin may be dosed to an area under the curve (AUC) of eight
instead of mg/m2.
Table 6. Risk factors in seminoma and non-seminoma after failure of
cisplatin-based first-line treatment
Favorable Unfavorable
Histology seminoma non-seminoma
Localization of
primary tumor
All except primary
mediastinal
non-seminoma
Primary mediastinal
non-seminoma
Response to
first-line
chemotherapy
CR/NED or PRm− PRm+ or SD or PD
Progression-free
interval
Three months or more
after last
chemotherapya
Less than 3 months after
last chemotherapy
Metastases at relapse Lymph-node or
pulmonary as only
metastatic sites
Extrapulmonary visceral
metastasesb
Serum tumor
markers at relapse
AFP normal HCG
≤1000 U/l
AFP elevated HCG
>1000 U/l
Salvage attempt First salvage Second or subsequent
salvage
aPatients with late relapse relapses >2 years have an inferior prognosis.
bLiver, bone or brain metastases.
CR, complete remission; NED, no evidence of disease after surgery;
PRm−, partial remission and negative tumor markers; PRm+, partial
remission and positive tumor markers; SD, stable disease; PD, progressive
disease; AFP, alpha-fetoprotein; HCG, human chorionic gonadotropin.
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than other cohorts with GCC relapses (supplementary material
S25, available at Annals of Oncology online). Patients with
resectable late relapse should undergo immediate surgical
removal of all tumor manifestations at an experienced
reference center irrespective of serum tumor marker levels
[62, 63]. No consensus could be achieved, however, on the
management of unresectable late relapse, although the majority
recommended CDCT (supplementary material S26, available at
Annals of Oncology online) [64].
special scenarios in seminoma and
non-seminoma
Human immunodeficiency virus (HIV)-positive GCC patients
should be managed in an identical fashion to patients without
an HIV infection. However, highly active antiretroviral therapy
should be given concurrently during chemotherapy and
antimicrobial prophylaxis instituted, if CD4 counts fall below
200 cells/µl (supplementary material S27, available at Annals of
Oncology online) [65, 66].
In patients with advanced metastatic GCC and/or those with
impeding organ failure orchiectomy should be postponed until
the completion of chemotherapy (supplementary material S28,
available at Annals of Oncology online). The high risk of life-
threatening treatment-related complications or even death in
these patients can be reduced by avoiding full-dose
chemotherapy as initial treatment [67]. However, data on how
to optimally administer such a pre-phase induction
chemotherapy are scarce. The majority of panelists considered
2 days of cisplatin plus etoposide an acceptable way to start
chemotherapy in patients with a very high-tumor burden and
normal renal function and continue with four cycles of full-
dose BEP or VIP from day 11 onwards, when the patients have
stabilized (supplementary material S29, available at Annals of
Oncology online). In patients presenting with additional acute
renal failure, bleomycin should not be used. The majority of
panelists opted to start pre-phase induction chemotherapy
either with carboplatin alone or with the combination of
carboplatin and etoposide and continue with four cycles of
full-dose BEP or VIP from on day 11 onwards when the
patients have stabilized and recovered with their renal function
(supplementary material S30, available at Annals of Oncology
online). In patients with chronically impaired renal function,
there was no consensus on the issue of replacing cisplatin by
carboplatin (supplementary material S31, available at Annals of
Oncology online).
Patients with brain metastases present a particular challenge.
There was consensus that these patients have an inferior
prognosis compared with other GCC patients. At initial
diagnosis, panelists recommended immediate upfront
chemotherapy. Opinions were divided, however, in respect to
additional surgery or irradiation (supplementary material S32,
available at Annals of Oncology online). In the even more
unfavorable patients relapsing with brain metastases, the
majority of panelists voted for full salvage chemotherapy, but
again no consensus could be achieved in respect to additional
treatments (supplementary material S33, available at Annals of
Oncology online).
There was a strong and unequivocal vote to immediately
transfer patients with advanced disease and particularly those
with imminent organ failure to units experienced in treating
these high-risk patients: with an agreement of about two-thirds
of the panelists these were defined as centers treating >10
patients for metastatic GCC per year including 5 for salvage or
intermediate or poor prognosis [68].
reproductive health, late toxic effects
and HRQoL
Testicular cancer patients are at risk to experience fertility
distress and difficulty in fathering children. Fertility problems
often precede GCC diagnosis and infertility is an accepted risk
factor for GCC development [69]. The fatherhood rate among
testicular cancer survivors wishing to father a child is ∼70%
within 15 years having a strong correlation with treatment
intensity. Compared with the general population, the 10-year
post-treatment paternity rate remains significantly reduced
[70–72]. No increased risk of malformations is found in
children of GCC survivors [73]. Patients should be counseled
about these figures and pre-chemotherapy semen
cryopreservation offered [74].
Male hypogonadism after treatment as defined by total
testosterone serum levels <8 nmol/l is frequent and varies
between 11% and 35% among GCC survivors [75].
Therefore, the determination of testosterone is
recommended during follow-up and replacement offered to
all patients with low testosterone levels and/or symptoms
of hypogonadism to prevent long-term
sequelae [76, 77].
There is about a two- to threefold increased risk of late
cardiovascular toxicity (coronary heart disease, myocardial
infarction, congestive heart failure and stroke) among GCC
survivors treated with chemotherapy or radiotherapy compared
with the general population, which is more prominent in GCC
patients treated at a younger age or treated with a combination
of chemotherapy and radiation [77–79]. Overall, the
cumulative risk of such events over 20 years may be as high as
18%. Death mainly from coronary heart disease accounts for a
higher overall non-cancer mortality among long-term GCC
survivors. The exact reasons for late cardiovascular toxicity are
unknown, but may be related to a direct endovascular damage
and accelerated atherosclerosis or vascular ageing induced by
cisplatin. The onset of a Raynaud phenomenon might possibly
represent a clinical biomarker to identify survivors with
augmented atherosclerosis, who could benefit from
prophylactic interventions [80–82].
The frequency of metabolic syndrome is also increased and
occurs in ∼20%–30% of long-term GCC survivors [77–80].
Particularly relevant is the fact that the onset of metabolic
syndrome is much earlier than expected from the general
population starting ∼3–5 years after GCC treatment [80].
Other clinical or subclinical organ toxicities such as
pulmonary toxicity, renal toxicity, ototoxicity and neurological
sequelae are frequent and dose-related [81, 82].
According to the available data, the relative risk of a second
solid non-germ-cell tumor is approximately doubled after
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radiotherapy or chemotherapy. The combination of both
treatment modalities is associated with a threefold increased
risk. The figures are particularly high for malignancies in the
gastrointestinal and urinary tract. Solid second tumors usually
occur ≥10 years after treatment as opposed to chemotherapy-
induced leukemias which commonly emerge within one decade
after treatment. The estimated cumulative risk of leukemia is
0.5% and 2%, after cumulative etoposide doses of <2 g/m2 and
>2 g/m2, respectively [83].
Health-related quality of life (HRQoL) in long-term GCC
survivors seems to be similar to the normal male population,
but persisting long-term treatment-related side-effects show a
strong association with both impaired physical and mental
HRQoL [84, 85]. The level of anxiety is higher in GCC
survivors than in the general male population, possibly
‘triggered’ by the fear of recurrence. Anxiety and fear of
recurrence might be higher in single or unemployed men and
those with a lower education. GCC survivors with a more
‘neurotic personality’ (e.g. higher level of nervousness and
vulnerability to stress) also seemed to have a higher level of
anxiety and fear of recurrence and to report more side-effects
[86–88].
The prevalence of self-reported chronic fatigue and cognitive
complaints are common among patients with GCC, but not
significantly related to cognitive test performance. No studies
have so far demonstrated an elevated rate of objectively
assessed cognitive difficulties in long-term GCC survivors
[88, 89].
As there will be an increasing number of GCC survivors in
all European countries, the aspects of late toxic effects and
HRQoL should be addressed in the management of all GCC
survivors [83]. GCC survivors need counseling on a healthy
lifestyle in order to minimize the risk factors such as smoking
and physical inactivity. Patients should be screened and treated
for known risk factors such as high blood pressure,
hyperlipidemia and testosterone deficiency. And, perhaps most
importantly, GCC patients should be provided with a written
cancer survivorship plan at the end of their treatment that
addresses late toxic effects and HRQoL in addition to the risks
of recurrence and cancer-specific follow-up.
follow-up schedules
The dramatic increase in the exposure to medical radiation
since the 1980s from 0.5 mSv to ∼3.0 mSv is threatening for
young GCC patients because of the related risk of radiation-
induced secondary tumors [90–92]. Many follow-up
recommendations that have been published most likely expose
GCC survivors to unnecessary radiation. Statistically, in long-
term GCC survivors, the risks from radiation exposure might
even be higher than the risk, e.g. from a late relapse GCC [93].
The issue of replacing CT by MRI scan was one area of
controversy, but considered as not feasible in the majority of
European countries by the majority of panelists. Rather every
effort should be made to reduce the frequency of CT scans and
limit their total number. Similarly, it was stressed that PET–CT
scanning has no role in the follow-up of GCC patients.
There were controversial discussions and several E-votes on
the issues of follow-up (supplementary material S34–39,
available at Annals of Oncology online). No consensus as to an
authoritative follow-up schedule or recommendation for an
optimal follow-up duration could be reached. However, those
suggested during the meeting closely resembled most recently
published follow-up schedules [94–96]. Several discussants
stressed the fact that recommendations for follow-up will have
to be adapted according to the national and institutional
requirements. These need to be, however, oriented towards
published recommendations and large differences avoided
[94–96]. Several aspects should be considered in designing
follow-up schedules: the schedules should be straightforward
and easy to follow, the risk of recurrence has to be taken into
account (e.g. high versus low risk), the localization of relapse
should be considered (e.g. retroperitoneal versus pulmonary
relapses) and the time to relapse should be incorporated into
follow-up plans (e.g. early versus late relapses). Except in rare
clinical circumstances or suspected late relapse, it was
recommended that no routine CT scans be carried out beyond
5 years of follow-up [23, 94–96].
summary
Whereas many of the discussions during the Third European
Consensus Conference on Diagnosis and Treatment of GCC
represented optimizing and fine tuning of the treatment
particularly of GCC patients with rare presentations and those,
who are ‘difficult-to-treat’, the goals for the majority of GCC
patients are straightforward: (i) close multidisciplinary
collaboration in diagnosis and management; (ii) active
involvement of patients in management decisions;
(iii) reducing treatment burden by offering surveillance
strategies to clinical stage I patients whenever possible;
(iv) maintaining cure and optimizing treatment as well as
supportive care for patients with metastatic disease;
(v) optimizing the care for GCC survivors by addressing
issues such as fertility, late toxic effects and HRQoL through
development of straightforward and rational follow-up and
survivorship plans.
There was a strong and uniform consensus that these goals
can best be achieved by centralization of care at experienced
centers particularly for patients with intermediate and poor
prognosis at initial presentation as well as for all relapsed GCC
patients. Too many patients with GCC still suffer from
unnecessary toxic effects or even die without ever having had
the chance of optimal expert treatment.
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